Keisuke Horikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keisuke Horikawa has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Christopher C. Goodnow
Garvan Institute of Medical Research, Sydney, Australia
14 shared publications - Anselm Enders
Division of Immunology and Infectious Diseases, John Curtin School of Medical Research, The Australian National University
6 shared publications Hirofumi Nishizumi
Department of Biophysics and Biochemistry, Graduate School of Science, University of Tokyo, 2‐11‐16, Yayoi, Bunkyo‐ku, Tokyo 113‐0032, Japan
3 shared publicationsIngrid E. Wertz
Genentech Inc., South San Francisco, CA, USA
3 shared publicationsKiyoshi Takatsu
Department of Immunology, Institute of Medical Science, University of Tokyo , Tokyo
3 shared publicationsWendy Sandoval
Genentech Inc., South San Francisco, CA, USA
3 shared publications
Latest Publications
- 18 September 2019
- Published by Springer Nature in Nature Immunology
- Vol. 20 (10) , 1299-1310
Denisovan, modern human and mouse TNFAIP3 alleles tune A20 phosphorylation and immunity
Resisting and tolerating microbes are alternative strategies to survive infection, but little is known about the evolutionary mechanisms controlling this balance. Here genomic analyses of anatomically modern humans, extinct Denisovan hominins and mice revealed a TNFAIP3 allelic series with alterations in the encoded immune response inhibitor A20. Each TNFAIP3 allele encoded substitutions at non-catalytic residues of the ubiquitin protease OTU domain that diminished IκB kinase-dependent phosphorylation and activation of A20. Two TNFAIP3 alleles encoding A20 proteins with partial phosphorylation deficits seemed to be beneficial by increasing immunity without causing spontaneous inflammatory disease: A20 T108A;I207L, originating in Denisovans and introgressed in modern humans throughout Oceania, and A20 I325N, from an N-ethyl-N-nitrosourea (ENU)-mutagenized mouse strain. By contrast, a rare human TNFAIP3 allele encoding an A20 protein with 95% loss of phosphorylation, C243Y, caused spontaneous inflammatory disease in humans and mice. Analysis of the partial-phosphorylation A20 I325N allele in mice revealed diminished tolerance of bacterial lipopolysaccharide and poxvirus inoculation as tradeoffs for enhanced immunity.
- 18 September 2019
- Published by Springer Nature in Nature Immunology
- Vol. 20 (10) , 1299-1310
Denisovan, modern human and mouse TNFAIP3 alleles tune A20 phosphorylation and immunity
Resisting and tolerating microbes are alternative strategies to survive infection, but little is known about the evolutionary mechanisms controlling this balance. Here genomic analyses of anatomically modern humans, extinct Denisovan hominins and mice revealed a TNFAIP3 allelic series with alterations in the encoded immune response inhibitor A20. Each TNFAIP3 allele encoded substitutions at non-catalytic residues of the ubiquitin protease OTU domain that diminished IκB kinase-dependent phosphorylation and activation of A20. Two TNFAIP3 alleles encoding A20 proteins with partial phosphorylation deficits seemed to be beneficial by increasing immunity without causing spontaneous inflammatory disease: A20 T108A;I207L, originating in Denisovans and introgressed in modern humans throughout Oceania, and A20 I325N, from an N-ethyl-N-nitrosourea (ENU)-mutagenized mouse strain. By contrast, a rare human TNFAIP3 allele encoding an A20 protein with 95% loss of phosphorylation, C243Y, caused spontaneous inflammatory disease in humans and mice. Analysis of the partial-phosphorylation A20 I325N allele in mice revealed diminished tolerance of bacterial lipopolysaccharide and poxvirus inoculation as tradeoffs for enhanced immunity.
- 14 May 2019
- Published by Wiley in Immunology & Cell Biology
- Vol. 97 (8) , 740-752
CARD11 is dispensable for homeostatic responses and suppressive activity of peripherally induced FOXP3+ regulatory T cells
FOXP3+ regulatory T (Treg) cells are essential for immunological tolerance and immune homeostasis. Despite a great deal of interest in modulating their number and function for the treatment of autoimmune disease or cancer, the precise mechanisms that control the homeostasis of Treg cells remain unclear. We report a new ENU‐induced mutant mouse, loco, with atopic dermatitis and Treg cell deficiency typical of Card11 loss‐of‐function mutants. Three distinct single nucleotide variants were found in the Card11 introns 2, 10 and 20 that cause the loss of CARD11 expression in these mutant mice. These mutations caused the loss of thymic‐derived, NRP1+ Treg cells in neonatal and adult loco mice, however residual peripherally‐induced NRP1‐ Treg cells remained. These peripherally generated Treg cells could be expanded in vivo by administration of IL‐2:anti‐IL‐2 complexes, indicating this key homeostatic signaling axis remained intact in CARD11‐deficient Treg cells. Furthermore, these expanded Treg cells could mediate near normal suppression of activated, conventional CD4+ T cells, suggesting that CARD11 is dispensable for Treg cell function. In addition to shedding light on the requirements for CARD11 in Treg cell homeostasis and function, these data reveal novel non‐coding Card11 loss‐of‐function mutations that impair expression of this critical immune‐regulatory protein.
- 14 May 2019
- Published by Wiley in Immunology & Cell Biology
- Vol. 97 (8) , 740-752
CARD11 is dispensable for homeostatic responses and suppressive activity of peripherally induced FOXP3+ regulatory T cells
FOXP3+ regulatory T (Treg) cells are essential for immunological tolerance and immune homeostasis. Despite a great deal of interest in modulating their number and function for the treatment of autoimmune disease or cancer, the precise mechanisms that control the homeostasis of Treg cells remain unclear. We report a new ENU‐induced mutant mouse, loco, with atopic dermatitis and Treg cell deficiency typical of Card11 loss‐of‐function mutants. Three distinct single nucleotide variants were found in the Card11 introns 2, 10 and 20 that cause the loss of CARD11 expression in these mutant mice. These mutations caused the loss of thymic‐derived, NRP1+ Treg cells in neonatal and adult loco mice, however residual peripherally‐induced NRP1‐ Treg cells remained. These peripherally generated Treg cells could be expanded in vivo by administration of IL‐2:anti‐IL‐2 complexes, indicating this key homeostatic signaling axis remained intact in CARD11‐deficient Treg cells. Furthermore, these expanded Treg cells could mediate near normal suppression of activated, conventional CD4+ T cells, suggesting that CARD11 is dispensable for Treg cell function. In addition to shedding light on the requirements for CARD11 in Treg cell homeostasis and function, these data reveal novel non‐coding Card11 loss‐of‐function mutations that impair expression of this critical immune‐regulatory protein.
- Open Access
- 12 July 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (9) , 2759-2776
Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM
CD79B and MYD88 mutations are frequently and simultaneously detected in B cell malignancies. It is not known if these mutations cooperate or how crosstalk occurs. Here we analyze the consequences of CD79B and MYD88L265P mutations individually and combined in normal activated mouse B lymphocytes. CD79B mutations alone increased surface IgM but did not enhance B cell survival, proliferation, or altered NF-κB responsive markers. Conversely, B cells expressing MYD88L265P decreased surface IgM coupled with accumulation of endoglycosidase H–sensitive IgM intracellularly, resembling the trafficking block in anergic B cells repeatedly stimulated by self-antigen. Mutation or overexpression of CD79B counteracted the effect of MYD88L265P. In B cells chronically stimulated by self-antigen, CD79B and MYD88L265P mutations in combination, but not individually, blocked peripheral deletion and triggered differentiation into autoantibody secreting plasmablasts. These results reveal that CD79B and surface IgM constitute a rate-limiting checkpoint against B cell dysregulation by MYD88L265P and provide an explanation for the co-occurrence of MYD88 and CD79B mutations in lymphomas.
- 12 July 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (9) , 2759-2776
Open AccessSynergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM
CD79B and MYD88 mutations are frequently and simultaneously detected in B cell malignancies. It is not known if these mutations cooperate or how crosstalk occurs. Here we analyze the consequences of CD79B and MYD88L265P mutations individually and combined in normal activated mouse B lymphocytes. CD79B mutations alone increased surface IgM but did not enhance B cell survival, proliferation, or altered NF-κB responsive markers. Conversely, B cells expressing MYD88L265P decreased surface IgM coupled with accumulation of endoglycosidase H–sensitive IgM intracellularly, resembling the trafficking block in anergic B cells repeatedly stimulated by self-antigen. Mutation or overexpression of CD79B counteracted the effect of MYD88L265P. In B cells chronically stimulated by self-antigen, CD79B and MYD88L265P mutations in combination, but not individually, blocked peripheral deletion and triggered differentiation into autoantibody secreting plasmablasts. These results reveal that CD79B and surface IgM constitute a rate-limiting checkpoint against B cell dysregulation by MYD88L265P and provide an explanation for the co-occurrence of MYD88 and CD79B mutations in lymphomas.
- 12 June 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (26) , E5216-E5225
Systems-guided forward genetic screen reveals a critical role of the replication stress response protein ETAA1 in T cell clonal expansion
Significance: T cells are required for control of many intracellular infections, and a critical component of T cell immunity is the proliferative expansion of effector T cells upon stimulation. Using a forward-based genetic screen, we identify the mouse Etaa1 gene as critically important for T cell proliferative expansion after vaccination and during infection. Consistent with recent findings that ETAA1 prevents DNA damage during proliferation, our data demonstrate elevated DNA damage within Etaa1 -deficient effector T cells, which likely leads to cell death. This phenotype is restricted to effector T cell proliferation, with T cell development and other immune parameters remaining normal. Thus, ETAA1 may represent a novel drug target to selectively suppress pathological T cell responses in transplantation or autoimmunity.
- 12 June 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (26) , E5216-E5225
Systems-guided forward genetic screen reveals a critical role of the replication stress response protein ETAA1 in T cell clonal expansion
Significance: T cells are required for control of many intracellular infections, and a critical component of T cell immunity is the proliferative expansion of effector T cells upon stimulation. Using a forward-based genetic screen, we identify the mouse Etaa1 gene as critically important for T cell proliferative expansion after vaccination and during infection. Consistent with recent findings that ETAA1 prevents DNA damage during proliferation, our data demonstrate elevated DNA damage within Etaa1 -deficient effector T cells, which likely leads to cell death. This phenotype is restricted to effector T cell proliferation, with T cell development and other immune parameters remaining normal. Thus, ETAA1 may represent a novel drug target to selectively suppress pathological T cell responses in transplantation or autoimmunity.
- Open Access
- 10 November 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 13381
IgD attenuates the IgM-induced anergy response in transitional and mature B cells
Self-tolerance by clonal anergy of B cells is marked by an increase in IgD and decrease in IgM antigen receptor surface expression, yet the function of IgD on anergic cells is obscure. Here we define the RNA landscape of thein vivoanergy response, comprising 220 induced sequences including a core set of 97. Failure to co-express IgD with IgM decreases overall expression of receptors for self-antigen, but paradoxically increases the core anergy response, exemplified by increasedSdc1encoding the cell surface marker syndecan-1. IgD expressed on its own is nevertheless competent to induce calcium signalling and the core anergy mRNA response. Syndecan-1 induction correlates with reduction of surface IgM and is exaggerated without surface IgD in many transitional and mature B cells. These results show that IgD attenuates the response to self-antigen in anergic cells and promotes their accumulation. In this way, IgD minimizes tolerance-induced holes in the pre-immune antibody repertoire.
- 10 November 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 13381
Open AccessIgD attenuates the IgM-induced anergy response in transitional and mature B cells
Self-tolerance by clonal anergy of B cells is marked by an increase in IgD and decrease in IgM antigen receptor surface expression, yet the function of IgD on anergic cells is obscure. Here we define the RNA landscape of thein vivoanergy response, comprising 220 induced sequences including a core set of 97. Failure to co-express IgD with IgM decreases overall expression of receptors for self-antigen, but paradoxically increases the core anergy response, exemplified by increasedSdc1encoding the cell surface marker syndecan-1. IgD expressed on its own is nevertheless competent to induce calcium signalling and the core anergy mRNA response. Syndecan-1 induction correlates with reduction of surface IgM and is exaggerated without surface IgD in many transitional and mature B cells. These results show that IgD attenuates the response to self-antigen in anergic cells and promotes their accumulation. In this way, IgD minimizes tolerance-induced holes in the pre-immune antibody repertoire.
- 22 September 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (12) , 1604-1608
Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo
The MYD88L265P mutation is found in 2% to 10% of chronic lymphocytic leukemia, 29% of activated B-cell type diffuse large B-cell lymphoma and 90% of Waldenström macroglobulinemia, making it conceptually attractive to treat these malignancies with inhibitors of endosomal Toll-like receptors (TLR9, TLR7) that activate MYD88. Here we show that genetic inhibition of endosomal TLRs has the opposite effect on accumulation of MYD88L265P B cells in vitro and in vivo. Activated mature B cells from wild-type, Unc93b13d/3d-mutant, or Tlr9-deficient mice were transduced with retrovirus encoding MYD88L265P and analyzed either in vitro or after transplantation into Rag1−/− recipient mice. Unc93b13d/3d mutation, which blocks TLR9 and TLR7 signaling, or Tlr9 deficiency suppressed MYD88L265P B-cell growth in vitro but paradoxically increased in vivo accumulation of MYD88L265P B cells as CD19low plasmablasts by 10- to 100-fold. These results reveal an unexpected, powerful inhibitory effect of TLR9 on MYD88L265P B-cell proliferation and differentiation that appears independent of TLR7, and they provide a preclinical indicator for caution in clinical trials of TLR7/9 inhibitors for MYD88L265P B-cell malignancies. Key Points Inhibiting endosomal TLRs suppresses MYD88L265P B-cell proliferation in vitro. Inhibition of endosomal TLRs paradoxically enhances accumulation of MYD88L265P B cells as plasmablasts in vivo.
- 22 September 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (12) , 1604-1608
Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo
The MYD88L265P mutation is found in 2% to 10% of chronic lymphocytic leukemia, 29% of activated B-cell type diffuse large B-cell lymphoma and 90% of Waldenström macroglobulinemia, making it conceptually attractive to treat these malignancies with inhibitors of endosomal Toll-like receptors (TLR9, TLR7) that activate MYD88. Here we show that genetic inhibition of endosomal TLRs has the opposite effect on accumulation of MYD88L265P B cells in vitro and in vivo. Activated mature B cells from wild-type, Unc93b13d/3d-mutant, or Tlr9-deficient mice were transduced with retrovirus encoding MYD88L265P and analyzed either in vitro or after transplantation into Rag1−/− recipient mice. Unc93b13d/3d mutation, which blocks TLR9 and TLR7 signaling, or Tlr9 deficiency suppressed MYD88L265P B-cell growth in vitro but paradoxically increased in vivo accumulation of MYD88L265P B cells as CD19low plasmablasts by 10- to 100-fold. These results reveal an unexpected, powerful inhibitory effect of TLR9 on MYD88L265P B-cell proliferation and differentiation that appears independent of TLR7, and they provide a preclinical indicator for caution in clinical trials of TLR7/9 inhibitors for MYD88L265P B-cell malignancies. Key Points Inhibiting endosomal TLRs suppresses MYD88L265P B-cell proliferation in vitro. Inhibition of endosomal TLRs paradoxically enhances accumulation of MYD88L265P B cells as plasmablasts in vivo.
- 13 January 2016
- Published by Springer Nature in Nature
- Vol. 532 (7599) , 402
Erratum: Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation
- 13 January 2016
- Published by Springer Nature in Nature
- Vol. 532 (7599) , 402
Erratum: Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation
- 9 December 2015
- Published by Springer Nature in Nature
- Vol. 528 (7582) , 370-375
Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation
Inactivation of the TNFAIP3 gene, encoding the A20 protein, is associated with critical inflammatory diseases including multiple sclerosis, rheumatoid arthritis and Crohn's disease. However, the role of A20 in attenuating inflammatory signalling is unclear owing to paradoxical in vitro and in vivo findings. Here we utilize genetically engineered mice bearing mutations in the A20 ovarian tumour (OTU)-type deubiquitinase domain or in the zinc finger-4 (ZnF4) ubiquitin-binding motif to investigate these discrepancies. We find that phosphorylation of A20 promotes cleavage of Lys63-linked polyubiquitin chains by the OTU domain and enhances ZnF4-mediated substrate ubiquitination. Additionally, levels of linear ubiquitination dictate whether A20-deficient cells die in response to tumour necrosis factor. Mechanistically, linear ubiquitin chains preserve the architecture of the TNFR1 signalling complex by blocking A20-mediated disassembly of Lys63-linked polyubiquitin scaffolds. Collectively, our studies reveal molecular mechanisms whereby A20 deubiquitinase activity and ubiquitin binding, linear ubiquitination, and cellular kinases cooperate to regulate inflammation and cell death.
- 9 December 2015
- Published by Springer Nature in Nature
- Vol. 528 (7582) , 370-375
Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation
Inactivation of the TNFAIP3 gene, encoding the A20 protein, is associated with critical inflammatory diseases including multiple sclerosis, rheumatoid arthritis and Crohn's disease. However, the role of A20 in attenuating inflammatory signalling is unclear owing to paradoxical in vitro and in vivo findings. Here we utilize genetically engineered mice bearing mutations in the A20 ovarian tumour (OTU)-type deubiquitinase domain or in the zinc finger-4 (ZnF4) ubiquitin-binding motif to investigate these discrepancies. We find that phosphorylation of A20 promotes cleavage of Lys63-linked polyubiquitin chains by the OTU domain and enhances ZnF4-mediated substrate ubiquitination. Additionally, levels of linear ubiquitination dictate whether A20-deficient cells die in response to tumour necrosis factor. Mechanistically, linear ubiquitin chains preserve the architecture of the TNFR1 signalling complex by blocking A20-mediated disassembly of Lys63-linked polyubiquitin scaffolds. Collectively, our studies reveal molecular mechanisms whereby A20 deubiquitinase activity and ubiquitin binding, linear ubiquitination, and cellular kinases cooperate to regulate inflammation and cell death.
- Open Access
- 1 October 2015
- Published by American Society of Hematology in Blood
- Vol. 126 (14) , 1658-1669
Omenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency
Key Points: Functional reversion of a germline CARD11 mutation in T cells is associated with the development of Omenn syndrome. Defective thymic T-cell development and peripheral lymphopenia are no prerequisite for the development of Omenn syndrome.
- 1 October 2015
- Published by American Society of Hematology in Blood
- Vol. 126 (14) , 1658-1669
Open AccessOmenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency
Key Points: Functional reversion of a germline CARD11 mutation in T cells is associated with the development of Omenn syndrome. Defective thymic T-cell development and peripheral lymphopenia are no prerequisite for the development of Omenn syndrome.
- Open Access
- 31 July 2014
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 5, 367
Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation
Pattern recognition receptors (PRRs) expressed on immune cells are crucial for the early detection of invading pathogens, in initiating early innate immune response and in orchestrating the adaptive immune response. PRRs are activated by specific pathogen-associated molecular patterns (PAMPs) that are present in pathogenic microbes or nucleic acids of viruses or bacteria. However, inappropriate activation of these PRRs, such as the Toll-like receptors (TLRs), due to genetic lesions or chronic inflammation has been demonstrated to be a major cause of many haematological malignancies. Gain-of-function mutations in the TLR adaptor protein MYD88 found in 39% of the activated B cell type of diffuse large B cell lymphomas (ABC-DLBCL) and almost 100% of Waldenström’s macroglobulinemia (WM) further highlight the involvement of TLRs in these malignancies. MYD88 mutations result in the chronic activation of TLR signalling pathways, thus the constitutive activation of the transcription factor NFκB to promote cell survival and proliferation. These recent insights into TLR pathway driven malignancies warrant the need for a better understanding of TLRs in cancers and the development of novel anti-cancer therapies targeting TLRs. This review focuses on Toll-like receptors function and signalling in normal or inflammatory conditions, and how mutations can also hijack the TLR signalling pathways to give rise to cancer. Lastly, we discuss how potential therapeutic agents could be used to restore normal responses to TLRs and have long lasting anti-tumour effects.
- 31 July 2014
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 5, 367
Open AccessToll-Like Receptors and Cancer: MYD88 Mutation and Inflammation
Pattern recognition receptors (PRRs) expressed on immune cells are crucial for the early detection of invading pathogens, in initiating early innate immune response and in orchestrating the adaptive immune response. PRRs are activated by specific pathogen-associated molecular patterns (PAMPs) that are present in pathogenic microbes or nucleic acids of viruses or bacteria. However, inappropriate activation of these PRRs, such as the Toll-like receptors (TLRs), due to genetic lesions or chronic inflammation has been demonstrated to be a major cause of many haematological malignancies. Gain-of-function mutations in the TLR adaptor protein MYD88 found in 39% of the activated B cell type of diffuse large B cell lymphomas (ABC-DLBCL) and almost 100% of Waldenström’s macroglobulinemia (WM) further highlight the involvement of TLRs in these malignancies. MYD88 mutations result in the chronic activation of TLR signalling pathways, thus the constitutive activation of the transcription factor NFκB to promote cell survival and proliferation. These recent insights into TLR pathway driven malignancies warrant the need for a better understanding of TLRs in cancers and the development of novel anti-cancer therapies targeting TLRs. This review focuses on Toll-like receptors function and signalling in normal or inflammatory conditions, and how mutations can also hijack the TLR signalling pathways to give rise to cancer. Lastly, we discuss how potential therapeutic agents could be used to restore normal responses to TLRs and have long lasting anti-tumour effects.